Satellos Research Development vs Depreciation And Amortization Analysis

MSCL Stock

0.70 0.01 1.45%

Satellos Bioscience financial indicator trend analysis is much more than just breaking down Satellos Bioscience prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Satellos Bioscience is a good investment. Please check the relationship between Satellos Bioscience Research Development and its Depreciation And Amortization accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Satellos Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Research Development vs Depreciation And Amortization

Research Development vs Depreciation And Amortization Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Satellos Bioscience Research Development account and Depreciation And Amortization. At this time, the significance of the direction appears to have no relationship.

The correlation between Satellos Bioscience's Research Development and Depreciation And Amortization is 0.01. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of Satellos Bioscience, assuming nothing else is changed. The correlation between historical values of Satellos Bioscience's Research Development and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Satellos Bioscience are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Research Development i.e., Satellos Bioscience's Research Development and Depreciation And Amortization go up and down completely randomly.

Correlation Coefficient

0.01

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Research Development

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Most indicators from Satellos Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Satellos Bioscience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Satellos Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

As of the 25th of November 2025, Selling General Administrative is likely to grow to about 8.6 M, while Tax Provision is likely to drop 0.00.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	8.4M	15.5M	27.8M	29.2M
Cost Of Revenue	3.7M	8.8M	20K	19K

Total Operating Expenses Cost Of Revenue

Satellos Bioscience fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Non Current Liabilities Total	Inventory	Intangible Assets	Other Assets	Good Will	Capital Surpluse	Cash And Equivalents
Total Assets		0.81	0.84	1.0	0.55	-0.99	-0.97	0.92	0.99	0.09	1.0	0.76	0.85	0.78	0.94	0.86	1.0	0.99	-0.86	-0.86	-0.72	-0.95	0.86	0.86	0.92	0.93
Other Current Liab	0.81		0.96	0.8	0.87	-0.74	-0.89	0.7	0.72	0.52	0.78	0.87	0.83	0.32	0.63	0.95	0.77	0.84	-0.45	-0.45	-0.58	-0.81	0.57	0.57	0.74	0.77
Total Current Liabilities	0.84	0.96		0.84	0.7	-0.81	-0.92	0.82	0.79	0.41	0.82	0.82	0.87	0.48	0.74	0.98	0.81	0.88	-0.53	-0.53	-0.52	-0.87	0.74	0.74	0.85	0.87
Total Stockholder Equity	1.0	0.8	0.84		0.55	-0.99	-0.97	0.92	0.99	0.08	1.0	0.75	0.86	0.79	0.94	0.85	1.0	0.99	-0.87	-0.87	-0.73	-0.95	0.86	0.86	0.92	0.93
Property Plant And Equipment Net	0.55	0.87	0.7	0.55		-0.43	-0.63	0.4	0.42	0.68	0.51	0.71	0.53	-0.04	0.29	0.69	0.5	0.59	-0.21	-0.21	-0.53	-0.52	0.13	0.13	0.35	0.4
Net Debt	-0.99	-0.74	-0.81	-0.99	-0.43		0.95	-0.94	-1.0	0.01	-0.99	-0.7	-0.85	-0.86	-0.98	-0.83	-0.99	-0.98	0.89	0.89	0.67	0.95	-0.92	-0.92	-0.95	-0.95
Retained Earnings	-0.97	-0.89	-0.92	-0.97	-0.63	0.95		-0.94	-0.95	-0.24	-0.96	-0.81	-0.85	-0.69	-0.91	-0.93	-0.96	-0.99	0.8	0.8	0.6	0.98	-0.83	-0.83	-0.9	-0.91
Accounts Payable	0.92	0.7	0.82	0.92	0.4	-0.94	-0.94		0.94	0.1	0.92	0.63	0.71	0.83	0.96	0.8	0.92	0.95	-0.9	-0.9	-0.49	-0.95	0.89	0.89	0.87	0.86
Cash	0.99	0.72	0.79	0.99	0.42	-1.0	-0.95	0.94		-0.02	0.99	0.69	0.82	0.86	0.98	0.81	0.99	0.97	-0.92	-0.92	-0.67	-0.95	0.91	0.91	0.94	0.93
Non Current Assets Total	0.09	0.52	0.41	0.08	0.68	0.01	-0.24	0.1	-0.02		0.02	0.55	0.02	-0.42	-0.08	0.39	0.01	0.18	0.16	0.16	-0.23	-0.08	-0.16	-0.16	-0.06	-0.03
Cash And Short Term Investments	1.0	0.78	0.82	1.0	0.51	-0.99	-0.96	0.92	0.99	0.02		0.72	0.86	0.81	0.95	0.83	1.0	0.98	-0.88	-0.88	-0.71	-0.95	0.87	0.87	0.93	0.94
Net Receivables	0.76	0.87	0.82	0.75	0.71	-0.7	-0.81	0.63	0.69	0.55	0.72		0.69	0.26	0.63	0.89	0.72	0.79	-0.48	-0.48	-0.66	-0.7	0.57	0.57	0.68	0.7
Common Stock Shares Outstanding	0.85	0.83	0.87	0.86	0.53	-0.85	-0.85	0.71	0.82	0.02	0.86	0.69		0.61	0.75	0.88	0.86	0.83	-0.54	-0.54	-0.61	-0.82	0.81	0.81	0.93	0.95
Other Current Assets	0.78	0.32	0.48	0.79	-0.04	-0.86	-0.69	0.83	0.86	-0.42	0.81	0.26	0.61		0.9	0.46	0.82	0.74	-0.89	-0.89	-0.44	-0.76	0.89	0.89	0.81	0.78
Other Stockholder Equity	0.94	0.63	0.74	0.94	0.29	-0.98	-0.91	0.96	0.98	-0.08	0.95	0.63	0.75	0.9		0.76	0.95	0.94	-0.94	-0.94	-0.55	-0.94	0.94	0.94	0.91	0.9
Total Liab	0.86	0.95	0.98	0.85	0.69	-0.83	-0.93	0.8	0.81	0.39	0.83	0.89	0.88	0.46	0.76		0.83	0.89	-0.56	-0.56	-0.53	-0.88	0.76	0.76	0.86	0.87
Total Current Assets	1.0	0.77	0.81	1.0	0.5	-0.99	-0.96	0.92	0.99	0.01	1.0	0.72	0.86	0.82	0.95	0.83		0.98	-0.88	-0.88	-0.71	-0.95	0.88	0.88	0.93	0.94
Common Stock	0.99	0.84	0.88	0.99	0.59	-0.98	-0.99	0.95	0.97	0.18	0.98	0.79	0.83	0.74	0.94	0.89	0.98		-0.86	-0.86	-0.66	-0.97	0.85	0.85	0.91	0.91
Short Long Term Debt Total	-0.86	-0.45	-0.53	-0.87	-0.21	0.89	0.8	-0.9	-0.92	0.16	-0.88	-0.48	-0.54	-0.89	-0.94	-0.56	-0.88	-0.86		1.0	0.51	0.85	-0.8	-0.8	-0.75	-0.73
Non Current Liabilities Total	-0.86	-0.45	-0.53	-0.87	-0.21	0.89	0.8	-0.9	-0.92	0.16	-0.88	-0.48	-0.54	-0.89	-0.94	-0.56	-0.88	-0.86	1.0		0.51	0.85	-0.8	-0.8	-0.75	-0.73
Inventory	-0.72	-0.58	-0.52	-0.73	-0.53	0.67	0.6	-0.49	-0.67	-0.23	-0.71	-0.66	-0.61	-0.44	-0.55	-0.53	-0.71	-0.66	0.51	0.51		0.48	-0.48	-0.48	-0.6	-0.63
Intangible Assets	-0.95	-0.81	-0.87	-0.95	-0.52	0.95	0.98	-0.95	-0.95	-0.08	-0.95	-0.7	-0.82	-0.76	-0.94	-0.88	-0.95	-0.97	0.85	0.85	0.48		-0.86	-0.86	-0.9	-0.9
Other Assets	0.86	0.57	0.74	0.86	0.13	-0.92	-0.83	0.89	0.91	-0.16	0.87	0.57	0.81	0.89	0.94	0.76	0.88	0.85	-0.8	-0.8	-0.48	-0.86		1.0	0.96	0.94
Good Will	0.86	0.57	0.74	0.86	0.13	-0.92	-0.83	0.89	0.91	-0.16	0.87	0.57	0.81	0.89	0.94	0.76	0.88	0.85	-0.8	-0.8	-0.48	-0.86	1.0		0.96	0.94
Capital Surpluse	0.92	0.74	0.85	0.92	0.35	-0.95	-0.9	0.87	0.94	-0.06	0.93	0.68	0.93	0.81	0.91	0.86	0.93	0.91	-0.75	-0.75	-0.6	-0.9	0.96	0.96		1.0
Cash And Equivalents	0.93	0.77	0.87	0.93	0.4	-0.95	-0.91	0.86	0.93	-0.03	0.94	0.7	0.95	0.78	0.9	0.87	0.94	0.91	-0.73	-0.73	-0.63	-0.9	0.94	0.94	1.0

Click cells to compare fundamentals

Satellos Bioscience Account Relationship Matchups

Satellos Bioscience fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.1M	12.6M	6.2M	44.3M	73.0M	76.7M
Other Current Liab	91.5K	975.2K	1.4M	2.6M	2.2M	1.3M
Total Current Liabilities	220.0K	2.1M	2.8M	3.6M	5.2M	2.7M
Total Stockholder Equity	(183.8K)	10.5M	3.4M	40.7M	67.9M	71.3M
Property Plant And Equipment Net	1.7K	8.2K	9K	19K	5K	8.2K
Net Debt	375.8K	(4.9M)	(1.9M)	(22.1M)	(57.7M)	(54.8M)
Retained Earnings	(4.8M)	(20.3M)	(31.6M)	(47.5M)	(75.6M)	(71.8M)
Accounts Payable	128.5K	1.1M	1.5M	1.0M	3.0M	3.1M
Cash	717.5K	4.9M	1.9M	22.1M	57.7M	60.5M
Non Current Assets Total	1.7K	7.1M	4.0M	4.0M	5.0K	4.7K
Cash And Short Term Investments	717.5K	4.9M	1.9M	39.6M	69.9M	73.3M
Net Receivables	409.1K	528.0K	260.4K	583K	626K	443.5K
Liabilities And Stockholders Equity	1.1M	12.6M	6.2M	44.3M	73.0M	76.7M
Other Current Assets	1.1K	43.6K	48.6K	152K	2.5M	2.7M
Other Stockholder Equity	246.7K	2.5M	3.7M	5.0M	38.0M	39.8M
Total Liab	1.3M	2.1M	2.8M	3.6M	5.2M	2.9M
Total Current Assets	1.1M	5.4M	2.2M	40.3M	73.0M	76.7M
Common Stock	4.4M	28.3M	30.2M	61.9M	105.7M	111.0M

Pair Trading with Satellos Bioscience

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Satellos Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Satellos Bioscience will appreciate offsetting losses from the drop in the long position's value.

Moving together with Satellos Stock

0.74

HBP

Helix BioPharma Corp

Pair Corr

The ability to find closely correlated positions to Satellos Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Satellos Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Satellos Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Satellos Bioscience to buy it.

The correlation of Satellos Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Satellos Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Satellos Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Satellos Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Satellos Stock

Balance Sheet is a snapshot of the financial position of Satellos Bioscience at a specified time, usually calculated after every quarter, six months, or one year. Satellos Bioscience Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Satellos Bioscience and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Satellos currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Satellos Research Development vs Depreciation And Amortization Analysis

Research Development vs Depreciation And Amortization

Research Development vs Depreciation And Amortization Correlation Analysis

Correlation Coefficient

Research Development

Depreciation And Amortization

Satellos Bioscience fundamental ratios Correlations

Satellos Bioscience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Satellos Bioscience fundamental ratios Accounts

Pair Trading with Satellos Bioscience

Moving together with Satellos Stock

Other Information on Investing in Satellos Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Common Stock	- 0.99	Retained Earnings
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets